XIGRIS

This brand name is authorized in South Africa.

Active ingredients

The drug XIGRIS contains one active pharmaceutical ingredient (API):

1	Drotrecogin alfa UNII JGH8MYC891 - DROTRECOGIN ALFA (ACTIVATED)
	Drotrecogin alfa is a recombinant version of the natural plasma-derived activated Protein C, from which it differs only by unique oligosaccharides in the carbohydrate portion of the molecule. Activated Protein C is a crucial coagulation regulator. Furthermore, Activated Protein C is an important modulator of the systemic response to infection and has antithrombotic and profibrinolytic properties. Drotrecogin alfa has similar properties to those of endogenous human Activated Protein C.
	Read more about Drotrecogin alfa

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
XIGRIS Powder for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B01AD10	Drotrecogin alfa (activated)	B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AD Enzymes
Discover more medicines within B01AD10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
ZA	Health Products Regulatory Authority	36/8/0156